I 
109TH CONGRESS 
1ST SESSION H. R. 3550 
To amend the Public Health Service Act to improve provisions relating to 
Parkinson’s disease research. 
IN THE HOUSE OF REPRESENTATIVES 
JULY 28, 2005 
Mr. EVANS (for himself, Mrs. MALONEY, Mr. UDALL of Colorado, and Mr. 
BOEHLERT) introduced the following bill; which was referred to the Com-
mittee on Energy and Commerce 
A BILL 
To amend the Public Health Service Act to improve 
provisions relating to Parkinson’s disease research. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Morris K. Udall Par-
kinson’s Disease Research Act Amendments of 2005’’. 
SEC. 2. MORRIS K. UDALL PARKINSON’S DISEASE RE-
SEARCH ACT OF 1997. 
(a) FINDINGS.—Subsection (b) of section 603 of the 
Morris K. Udall Parkinson’s Disease Research Act of 
1997 (42 U.S.C. 284f note) is amended—
(1) in the subsection heading by striking 
‘‘FINDING’’and inserting ‘‘FINDINGS’’; and 
(2) by striking paragraph (1) and inserting the 
following: 
‘‘(1) FINDINGS.—Congress finds the following: 
‘‘(A) To take full advantage of the tremen-
dous potential for finding a cure or effective 
treatment, the Federal investment in Parkin-
son’s must be expanded, as well as the coordi-
nation strengthened among the National Insti-
tutes of Health research institutes. 
‘‘(B) The National Institutes of Health 
should invest in national health priorities focus-
ing on those with the greatest expense to soci-
ety or research with positive, translational, and 
measurable outcomes. Parkinson’s research, 
with its clear potential for translating basic re-
search into clinical results applicable to a wide 
array of disorders, is a prime example of re-
search that fulfills the National Institutes of 
Health’s national health priority criteria, in-
cluding the high expense to society.’’. 
(b) PUBLIC HEALTH SERVICE ACT.—Section 409B 
of the Public Health Service Act (42 U.S.C. 284f) is 
amended—
(1) in subsection (b), by striking paragraph (2) 
and inserting the following: 
‘‘(2) CONFERENCE.— 
‘‘(A) IN GENERAL.—The Director of NIH 
shall convene a coordinating and planning con-
ference every 2 years with relevant institutes 
and non-governmental organizations to conduct 
a thorough investigation of all Parkinson’s re-
search that is funded in whole or in part by the 
National Institutes of Health and to identify 
shortcomings and opportunities for more effec-
tive treatments and a cure for Parkinson’s dis-
ease. The Director shall report to Congress on 
the coordination among the institutes in car-
rying out such research. 
‘‘(B) RESEARCH INVESTMENT PLAN.— 
‘‘(i) IN
GENERAL.—The results of 
each conference convened under subpara-
graph (A) shall be included in a research 
investment plan that provides for measur-
able results with the goals of better treat-
ments and a cure for Parkinson’s disease 
being the determining factors in the alloca-
tion of Parkinson’s disease research dol-
lars. The plan shall include an outline of
the manner in which to fully utilize the 
Udall Center program to ensure the con-
tinuation 
of 
a 
particular 
focus 
on 
translational research, including a clinical 
component. 
‘‘(ii) BUDGET AND IMPLEMENTATION 
STRATEGY.—The plan submitted under 
clause (i) shall include a budget (that in-
cludes both programmatic and dollar line 
items) and implementation strategy (that 
incorporates the use of special initiatives 
such as requests for applications, program 
announcements with set-asides, or similar 
directed research mechanisms) together 
with results to be reported back to Con-
gress. 
‘‘(C) SUBMISSIONS
TO
CONGRESS.—The 
plan under subparagraph (B) (including the 
budget and implementation strategy) and the 
expected results of plan implementation shall be 
submitted to Congress not later than 3 months 
after the conference is convened under subpara-
graph (A). Reports on the outcomes of the plan, 
including actual spending and actual results,
shall be submitted to Congress on an annual 
basis. 
‘‘(D) FUNDING.—The Secretary shall en-
sure that adequate funding is available under 
this section to carry out the activities described 
in the investment plan under subparagraph 
(B).’’; 
(2) in subsection (c)— 
(A) in paragraph (1)— 
(i) by striking ‘‘not more than 10’’; 
and 
(ii) by adding at the end the fol-
lowing: ‘‘The Director shall ensure that an 
additional center shall be funded under 
this paragraph to serve as the coordinating 
center to coordinate the activities con-
ducted by each of the centers funded under 
this paragraph to further focus and man-
age the interdisciplinary efforts of such 
centers.’’; 
(B) in paragraph (2)(A)(ii), by striking 
‘‘conduct basic and clinical research’’ and in-
serting ‘‘in carrying out research, ensure that a 
significant clinical component is provided for in 
addition to ongoing basic research’’; and
(C) by adding at the end the following: 
‘‘(5) REVIEW PROCESS.—The Director of NIH 
shall establish a review process with respect to appli-
cations received for grants under paragraph (1). 
Such process shall provide for the evaluation of ap-
plicants in a manner that recognizes the unique as-
pects of the clinical, coordination, and multidisci-
plinary components of the applicants.’’; 
(3) in subsection (d)— 
(A) by striking ‘‘is authorized to establish 
a grant program’’ and inserting ‘‘shall award 
grants’’; and 
(B) by inserting before the period at the 
end the following: ‘‘and shall be awarded in a 
manner consistent with the research investment 
plan under subsection (b)(2)(B)’’; and 
(4) by striking subsection (e) and inserting the 
following: 
‘‘(e) REPORT.—The Director of NIH, in consultation 
with the Director of the Centers for Disease Control and 
Prevention, shall conduct an investigation, and prepare 
and submit to the appropriate committees of Congress a 
report, on the incidence of Parkinson’s disease, including 
age, occupation, and geographic population clusters, and 
related environmental factors relating to such disease.
‘‘(f) AUTHORIZATION
OF APPROPRIATIONS.— For 
the purpose of carrying out this section, and section 301 
and this title with respect to research focused on Parkin-
son’s disease, there are authorized to be appropriated up 
to $100,000,000 for fiscal year 1998, such sums as may 
be necessary for each of the fiscal years 1999 and 2000, 
and such sums as may be necessary for fiscal years 2006 
and each subsequent fiscal year.’’. 
Æ